Aug 2026· Medical Oncology· Vol 43· 0 citations· 101 references
Medicine
TL;DR
This review outlines the molecular mechanisms driving neoantigen generation in CRC, including frameshift mutations, single-nucleotide variants, alternative RNA splicing, and circular RNA-derived epitopes, and evaluates neoantigen-directed therapeutic platforms, encompassing personalized neoantigen vaccines and adoptive T-cell therapies that are engineered to recognize neoantigen-derived epitopes.
Immunotherapy has reshaped the treatment landscape of colorectal cancer (CRC), with the clearest and most durable benefit established in mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) disease. However, framing CRC immunotherapy simply as "MSI-H responsive versus microsatellite stable (MSS) res...
Recent experimental platforms have been developed to validate neoantigen immunogenicity, which can be complemented by single-cell RNA/T-cell receptor sequencing to identify tumor-reactive T cell clones.
Takamasa Ishino, Yosuke Togashi· The FEBS Journal· 0 citations
ERVs are consistently expressed and immunogenic in GBM, representing a scalable, tumor-specific antigen source that may overcome limitations of low mutational burden and provide a proof-of-concept for personalized vaccines targeting ERV-derived neoantigens.
Kenan Zhang, Megan C. Benz, K. Hotchkiss et al.· Journal of Immunology· 0 citations
This review aims to critically analyze the immunogenic and oncogenic potential of CTAs, synthesize current preclinical and clinical evidence across distinct CTA subfamilies, and highlight innovative CTA-based immunotherapeutic strategies for the treatment of melanoma.
Suzana Lemke Lanius, B. Pacheco, Fernanda Severo Sabedra Sousa et al.· Pathology, Research and Prac...· 0 citations
Overall, cancer vaccines are unlikely to become universal stand-alone treatments for advanced solid tumors, and their most credible role may emerge in molecularly selected patients, adjuvant therapy, minimal residual disease, virus-associated malignancies, and rational combinations with checkpoint inhibitors or tumor m...
D. Rusciano· Frontiers in Cell and Develo...· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
